Heather Uelhof
Acute Care · O Fallon, MONPI 1881296788
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,148 of the $6,277 with a category attached, or 82.0%. 26 manufacturers reported payments, led by Medtronic at 30.9% of the total. Reporting peaked in 2023 at $2,555 and has fallen 72.9% since, to $692 in 2025. Among acute care clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $28.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$1K
- Johnson & Johnson$402
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$339
- Regeneron Healthcare Solutions, Inc.$299
- United Therapeutics Corporation$234
- plus $2K from 20 others
What the payments were for
- Travel & lodging$1,01916%
- Food & beverage$5,14882%
- Education$1102%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 35 | $1,937 |
| Boston Scientific | 25 | $1,238 |
| Johnson & Johnson | 27 | $402 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $339 |
| Regeneron Healthcare Solutions, Inc. | 12 | $299 |
| United Therapeutics Corporation | 8 | $234 |
| E.r. Squibb & Sons, L.L.C. | 9 | $232 |
| Novartis | 15 | $219 |
| Sanofi-aventis U.S. LLC | 6 | $152 |
| Impulse Dynamics (USA) Inc. | 8 | $146 |
| Pfizer | 7 | $142 |
| Cvrx, Inc. | 6 | $140 |
| Merck | 10 | $130 |
| Jazz Pharmaceuticals Inc. | 7 | $127 |
| Boehringer Ingelheim | 5 | $126 |
| AstraZeneca | 6 | $85 |
| Biosense Webster, Inc. | 2 | $78 |
| Actelion Pharmaceuticals US, Inc. | 3 | $59 |
| Cardiva Medical, Inc. | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Elutia, Inc. | 2 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Amgen | 1 | $14 |
| Harmony Biosciences LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,061
- WATCHMAN Access System$574
- WATCHMAN FLX$143
- LINQ II$112
How this compares
$6,277 in reported general payments places this provider in the 95th percentile of 272 acute care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $78,627 |
| MultaqDronedarone Hcl | 33 | $31,440 |
| XareltoRivaroxaban | 18 | $11,009 |
| Dofetilide | 24 | $4,542 |
| Metoprolol Succinate | 136 | $1,453 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 41 | $909 |
| SotalolSotalol Hcl | 37 | $844 |
| Amiodarone Hcl | 72 | $661 |
| Flecainide Acetate | 14 | $622 |
| Cephalexin | 65 | $277 |
| Diltiazem Hcl | 16 | $154 |
| Metoprolol Tartrate | 28 | $84 |
| Carvedilol | 11 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $78,627100 claims |
| Sanofi-aventis U.S. LLCMultaq | $152 | $31,44033 claims |
| Johnson & JohnsonXarelto | $402 | $11,00918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 272 acute care providers in Missouri.
Other acute care in O Fallon
- Molly CahillKansas City$22K
- Kristin PressChesterfield$14K
- Sarah HeaveyKansas City$9K
- Nedra HarringtonPotosi$8K
- Hunter SmithColumbia$7K
- Caroline MundhenkeKansas City$6K
- Jennifer ReganSaint Louis$5K
- Jena SchollCape Girardeau$5K
- Kayla TourvilleSaint Louis$5K
- Christa SinkSaint Louis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.